Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis
- PMID: 16855169
- DOI: 10.1196/annals.1351.040
Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis
Abstract
Osteoporosis (OP) occurs more frequently in patients with rheumatoid arthritis (RA) than in healthy individuals. Specific treatments of RA may increase susceptibility to OP, but at the same time decrease inflammatory activity, which is associated with accelerated bone loss. Treatment with TNF-alpha blockers might influence bone metabolism and prevent structural bone damage in RA, in particular at the periarticular level. Our aim was to assess the influence of anti-TNF-alpha therapy on bone metabolism in RA patients. To that end we evaluated a group of 30 RA patients [mean age 50.6 +/- 6.8 years; median disease duration 82 +/- 38 months; median disease activity score (DAS-28) 5.8 +/- 1.2: 70% of whom were positive for the rheumatoid factor IgM (>40 IU/mL)]. Patients were treated with stable therapy of prednisone (7.5 mg/day) and methotrexate (MTX = 10 mg/week). Eleven of these RA patients further received etanercept (25 mg, twice/weekly) and 10 infliximab (3 mg/kg on 0, 2, 6, and every 8 weeks thereafter). A control group included 10 RA patients with stable therapy (prednisone and MTX) and without anti-TNF-alpha therapy. All the patients fulfilled the ACR criteria for the diagnosis of adult RA and were treated for 6 months. Quantitative ultrasound (QUS) bone densitometry was performed at the metaphyses of the proximal phalanges of both hands with a DBM Sonic 1200 QUS device (IGEA, Carpi, Italy). Amplitude-dependent speed of sound (AD-SoS) was evaluated at base line and at 3 and 6 months. Bone mineral density (BMD) of the hip and lumbar spine (L1-L4) was determined by a densitometer (GE Lunar Prodigy, USA) at base line at after 6 months. Soluble bone turnover markers [osteocalcin (BGP) and deoxypyridinoline/creatinine (Dpd/Cr) ratio] were measured in all patients at the same times, using enzyme-linked immunosorbent assay tests. All data were compared using Wilcoxon signed rank test. Results were as follows: AD-SoS values were found increased by 1.3% after 6 months of treatment in the RA patients treated with anti-TNF-alpha therapy. On the contrary, the Ad-SoS levels decreased by 4.6% during the same period in the untreated RA group. BMD increased by 0.2% at lumbar spine and 0.1% at the hip in TNF-alpha-blocker-treated patients and decreased by 0.8% and 0.6% (at lumbar spine and at the hip, respectively) in RA patients without anti-TNF-alpha therapy. However, BMD variations were not significant. In RA patients treated with TNF-alpha blockers, BGP levels were found significantly increased (14.8 +/- 3.8 mg/mL vs. 22.4 +/- 4.2 mg/mL; P < 0.01) and Dpd/Cr levels were found significantly decreased (8.2 +/- 2.1 nM vs. 4.6 +/- 1.8 nM; P < 0.01) at 6 months when compared to base line values. On the contrary, there were no significant differences in the untreated RA patients concerning these latter parameters (BGP = 12.2 +/- 3.1 mg/mL vs. 10.8 +/- 2.8 mg/mL and Dpd/Cr = 8.9 +/- 2.4 nM vs. 10.2 +/- 1.8 nM, respectively). In conclusion, during 6 months of treatment of RA patients with TNF blockers, bone formation seems increased while bone resorption seems decreased. The reduced rate of OP appears to be supported by the same mechanisms involved in the decreased bone joint resorption during anti-TNF-alpha therapy, that is, the marked decrease of the proinflammatory (i.e., TNF-alpha) cytokine effects on bone metabolism.
Similar articles
-
[Are there any positive effects of TNF-alpha blockers on bone metabolism?].Reumatismo. 2006 Jul-Sep;58(3):199-205. doi: 10.4081/reumatismo.2006.199. Reumatismo. 2006. PMID: 17013436 Clinical Trial. Italian.
-
Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.Rheumatology (Oxford). 2005 Dec;44(12):1546-8. doi: 10.1093/rheumatology/kei082. Epub 2005 Nov 1. Rheumatology (Oxford). 2005. PMID: 16263785 Clinical Trial.
-
Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis.Ann N Y Acad Sci. 2006 Jun;1069:414-9. doi: 10.1196/annals.1351.039. Ann N Y Acad Sci. 2006. PMID: 16855168
-
Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease.Aliment Pharmacol Ther. 2011 Jun;33(12):1261-72. doi: 10.1111/j.1365-2036.2011.04667.x. Epub 2011 Apr 26. Aliment Pharmacol Ther. 2011. PMID: 21521250 Review.
-
Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy.Ann N Y Acad Sci. 2010 Apr;1193:153-9. doi: 10.1111/j.1749-6632.2009.05287.x. Ann N Y Acad Sci. 2010. PMID: 20398022 Review.
Cited by
-
Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over.Osteoporos Int. 2013 Sep;24(9):2483-92. doi: 10.1007/s00198-013-2321-x. Epub 2013 Mar 16. Osteoporos Int. 2013. PMID: 23504029
-
Histological changes in bone marrow after treatment of infliximab for rheumatoid arthritis.Clin Rheumatol. 2008 Apr;27(4):497-501. doi: 10.1007/s10067-007-0790-z. Epub 2007 Nov 27. Clin Rheumatol. 2008. PMID: 18060342 Clinical Trial.
-
Disease Activity and Bone Mineral Density of MCP Joints in Patients with Rheumatoid and Psoriatic Arthritis: Is There a Correlation?-A Study in Patients Treated with Methotrexate and an Anti-TNF α Agent.ISRN Rheumatol. 2013 Dec 7;2013:708323. doi: 10.1155/2013/708323. eCollection 2013. ISRN Rheumatol. 2013. PMID: 24381766 Free PMC article.
-
The correlation between phalangeal quantitative ultrasonography and dual energy x-ray absorptiometry in women with premature ovarian failure.Mcgill J Med. 2008 Jul;11(2):132-40. Mcgill J Med. 2008. PMID: 19148311 Free PMC article.
-
Chronic pediatric inflammatory diseases: effects on bone.Rev Endocr Metab Disord. 2008 Jun;9(2):107-22. doi: 10.1007/s11154-007-9070-0. Epub 2007 Dec 29. Rev Endocr Metab Disord. 2008. PMID: 18165904 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous